<DOC>
	<DOC>NCT01825395</DOC>
	<brief_summary>To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).</brief_summary>
	<brief_title>Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Age 18 years or older, Diagnosed with LEMS, If female, have a negative pregnancy test, and If premenopausal, be willing to practice an effective form of birth control during the study, Tested and found by ECG not to have a prolonged QT syndrome, Agree to have a second ECG at the time of peak drug effect, Has understood and signed the Informed Consent. Is known to have a sensitivity to 3, 4DAP, Has a history of: 1. past or current seizures, 2. cardiac arrhythmia, 3. hepatic, renal or hematologic disease, or 4. severe asthma, Is believed by the investigator to be unable to comply with the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>